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ABSTRACT
Despite extensive efforts, Protein Kinase Cs (PKCs) have proven to be an 
intractable target in cancer therapies. Traditionally it was accepted that PKCs act as 
tumour promoters, however new research suggests that PKCs may play an important 
role in the suppression of cancer. A challenge in targeting PKCs is the limited data 
available in patient samples. One of the PKC isozymes, PKC gamma, is thought to be 
present only in the brain and has been largely neglected in the context of cancer. 
Analysis of gene expression levels of PKC gamma in patient matched normal and 
colon cancer tissue samples revealed an up-regulation of the gene in the cancer tissue 
of 54% of the patients examined. Mechanistically we demonstrate that a reduction 
in the levels of PKC gamma in the colon cancer cells inhibits cell migration and foci 
formation. Further to this, we observe an increase in cell adhesion and proliferation 
following the reduction of PKC gamma levels in the cell. Thus, PKC gamma plays a key 
role in colon cancer; making it an important isozyme that needs to be reconsidered 
in the context of cancer therapies. 
INTRODUCTION 
The Protein Kinase C (PKC) family have been 
studied extensively as a group of proteins that promote 
cancer. This follows the initial discovery that PKCs are a 
receptor for the tumour-promoting phorbal esters [1–3]. 
This led to the development of several target therapies 
against PKCs in cancer [4–6], however recent evidence 
has emerged suggesting that PKCs can play a tumour 
suppressor role in cancer [7–9]. 
PKCs are a multigene family of serine/threonine 
kinases which together are expressed in a diverse range 
of tissues and have several biological functions. The 
9 PKC isozymes mediate several biological processes 
including cell adhesion, the cell-cycle and the regulation 
of apoptosis [10, 11]. All members of the PKC family 
share common basic structures; a flexible hinge segment 
linking a cell membrane targeting N-terminal regulatory 
moiety to a C-terminal catalytic domain [12, 13]. The 
regulatory moiety contains two discrete membrane 
targeting modules and a pseudosubstrate segment that 
maintains the enzyme in an inactive conformation 
[13, 14]. The maturation of PKCs into this conformation 
is dependent on sequential phosphorylation steps at three 
highly conserved sites termed the activation loop, the turn 
motif, and the hydrophobic motif [15–17]. Following these 
phosphorylation events, the protein is activated by specific 
secondary messengers that bind to the regulatory domain 
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to mediate the release of the pseudosubstrate segment 
from the active site [14, 18]. The 9 isozymes are classified 
according to their secondary messenger requirements; the 
conventional isozymes  (cPKCs: α, βI, βII, and γ) depend 
on diacylglycerol (DAG) and Ca2+ for their activation, the 
novel isozymes (nPKCs: δ, ε, η, and θ)  depend on DAG, 
but not Ca2+, and the atypical isozymes (aPKCs: ζ and λ/ι) 
do not require either DAG or Ca2+ [10, 19, 20]. 
Although PKCs have been studied intensively, 
their precise role in cancer remains elusive [20]. This is 
largely due to the difficulty in deciphering the specific 
role of individual isozymes. Immunohistochemical and 
biochemical studies indicate that altered expression of 
the PKC isozymes is variable and depends on the cancer 
type [4, 21, 22]. We have shown recently that PKC Beta 
II is downregulated in colon cancer which promotes IGF-
I-mediated cell survival [7]. In other studies, it has been 
shown that PKCζ overexpression in colon cancer cell lines 
decreases tumour formation in nude mice while loss of 
PKCζ is also associated with decreased tumourigenicity 
[23, 24]. Further to this, PKCα can both induce and 
supress colon cancer cell proliferation [25, 26]. The 
expression of PKCβ in breast, gastric and colon cancer has 
been subject to much debate and there are many studies 
presenting arguments for both up and down regulation of 
the isozyme in cancer cells and cancer tissue [5, 7, 27–31]. 
Collectively, these studies led to the development of 
several target therapies against cancer [4–6]. However, 
PKC inhibitors have proved unsuccessful as anti-cancer 
agents in clinical trials [4, 32] and recent evidence has 
come to the fore suggesting that PKCs can play a tumour 
suppressor role in cancer [7–9]. 
What is now clear is that the PKC isozymes have 
distinct functions. Clearly defining the expression pattern 
of individual PKC isozymes in cancer is essential in 
deciphering whether PKCs exhibit a tumour suppressor 
and/or a tumour promotor role. Traditionally, it was 
believed that PKC gamma is expressed only in the brain 
[33, 34] and consequentially it received very little attention 
in the context of cancer. However, in recent times some 
evidence has emerged suggesting that PKC gamma is 
also present in colon tissue [35] and colonic cells [36]. 
Moreover, further novel research indicates that PKC 
gamma influences the migratory capacity of many cell 
types [37–39]. Taken together, this challenges the view that 
PKC gamma is expressed only in the brain and suggests 
that a recalibration of our understanding of PKC gamma is 
important as we revisit the role of PKCs in cancer. 
In our study, we examined the expression of PKC 
gamma in colon cancer in vivo and in vitro to fully 
elucidate if the gene was present or absent in colon tissue 
and to understand whether its function was enhanced or 
reduced in this cancer. Keeping in mind that PKCs are 
differentially expressed across and within different tissues, 
our approach was to reduce any variability that may occur 
between patients by examining the expression of the PKC 
gamma coding gene in patients matched normal and colon 
cancer tissue. Interestingly, not only was the PKC gamma 
gene present in the tissue but it was also significantly up-
regulated in the colon cancer tissue compared to the normal 
tissue in over 50% of patients. To examine the functional 
implications of this, using siRNA knockdown for PKC 
gamma, we demonstrate that PKC gamma influences the 
transformed phenotype and more specifically, increases 
the migratory capacity of colon cancer cells. All this 
data combined, suggests that PKC gamma plays a role in 
promoting colon cancer. 
RESULTS 
The gene coding PKC gamma is up-regulated in 
colon cancer 
We have previously shown differential expression of 
the PKC isoforms in colon cancer [7]. To investigate the 
expression of the PKC gamma coding gene, we compared 
the expression of the gene in patients’ cancer tissue to 
patients’ matched normal distant tissue. We detected the 
gene coding PKC gamma in 13 out of a total of 23 patient 
samples and found that the presence or absence of the gene 
was not influenced by disease stage (Table 1). Taking the 
13 patient samples in which the gene was expressed, we 
next established an individual fold change for each patient. 
The results show that 54% of the patients demonstrate a 
significant up-regulation of the PKC gamma coding gene 
(Figure 1A). This up-regulation was not influenced by the 
progression of the disease as no significant difference was 
found between the percentages of patients with an up-
regulation in stage 2 or stage 3 of the disease (Figure 1B). 
Loss of PKC gamma influences the malignant 
phenotype in colon cancer cells 
Our data indicates that there is an up-regulation 
of the gene coding PKC gamma in over 50% of the 
colon cancer patients in our study. Considering this, we 
questioned if the loss of PKC Gamma would influence the 
transformed phenotype in vitro. 
Firstly, in order to select the cells which expressed 
the highest levels of PKC gamma we examined the levels 
of the gene coding for PKC gamma in three different colon 
cancer cell lines maintained in either 2-Dimensional or 
3-Dimensional growth conditions (Figure 2A). To further 
validate, this we also examined the protein expression of 
PKC Gamma in HT29 and HCT116 cell lines (Figure 2B). 
Together, the results demonstrate that HCT116 show the 
highest expression of PKC gamma at both a gene and protein 
level. Considering this, we reduced levels of PKC gamma in 
HCT116 cells using siRNA oligonucleotides (Figure 2C) and 
performed different functional cell based assays. 
We developed spheroids of the HCT116 cells and 
using these 3-dimensional cultures, we observed that loss 
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of PKC gamma in these cells resulted in a significant 
reduction in the size of the spheroids (Figure 2D, 
Supplementary Figure 1). Following this, we examined if 
the loss of PKC gamma would influence the cells ability 
to form colonies. Transfected HCT116 cells were seeded 
at very low densities and their capacity to develop colonies 
was monitored over a period of 10 days. Interestingly, 
cells demonstrated a significant reduction in colony size 
and number when PKC gamma levels were reduced in 
the cell (Figure 2E). We next tested if PKC gamma loss 
would influence the migratory capacity of HCT116 cells. 
To conduct this, we utilized ibidi® inserts and carried out 
a wound migration assay. Transfected HCT116 cells were 
seeded around the insert at 100% confluency, 24 hours 
later the insert was removed and cells were monitored as 
they migrated into the space created by the insert. Here, 
we observed a significant reduction in the ability of cells 
to migrate into the wound when PKC gamma levels were 
reduced (Figure 2F). Taken together, this data strongly 
supports the hypothesis that PKC gamma promotes a 
transformed phenotype. 
Loss of PKC gamma enhances the proliferation 
and adherence of colon cancer cells 
Having shown that loss of PKC gamma inhibits cell 
migration and foci formation, we next wanted to investigate 
the consequences of this loss on cell proliferation and 
adhesion. To do this, cellular levels of PKC gamma were 
reduced using a siRNA oligonucleotide. Cells were plated 
in wells of an E-plate and their behaviour was  monitored 
using RTCA as previously described [40]. Results indicate 
that HCT116 cells proliferate significantly faster when 
PKC gamma is reduced in the cells (Figure 3A). To further 
validate this we conducted a traditional cell count assay 
and again we observed an increase in cell number when 
PKC gamma is reduced in both HCT116 cells (Figure 3B) 
and HT29 cells (Figure 3C). To investigate the effects on 
cell adhesion, data was extracted from the platform over 
the first 5 hours of cell monitoring. Results show that 
HCT116 cells in which PKC gamma levels have been 
reduced adhere almost twice as fast as cells treated with the 
scrambled siRNA oligonucleotide (Figure 4A). To confirm 
Table 1: Characteristics of the cohort of colorectal cancer (CRC) patients used to analysis the 
mRNA levels of PKC gamma
Patient Number Gender Age Stage PRKCG*
 1 M 55 1 +
 2 F 45 2 +
 3 M 68 2 +
 4 M 85 2 +
 5 M 79 2 +
 6 F 83 2 +
 7 M 82 2 +
 8 M 82 2 +
 9 F 53 2 +
10 M 65 2 +
11 M 77 2 –
12 F 59 2 –
13 M 80 2 –
14 F 63 2 –
15 M 81 2 –
16 M 70 3 +
17 M 56 3 +
18 F 69 3 +
19 F 66 3 –
20 M 59 3 –
21 M 68 3 –
22 F 69 3 –
23 M 59 3 –
*+ and – refer to absolute presence or absence of PRKCG.
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this, we used a traditional assay to show that loss of PKC 
gamma in HCT116 cells results in a 40% increase in cell 
adhesion (Figure 4B). This data suggests that PKC gamma 
plays an important role in regulating the proliferation and 
adhesion of colon cancer cells. 
DISCUSSION 
Using tissue samples we show that the gene coding 
for PKC gamma is up-regulated in 54% of patient’s colon 
cancer tissue when compared to patient matched normal 
tissue. Further to this, suppression of PKC gamma reduces 
the migratory capacity of colon cancer cells. This study 
challenges traditional views that PKC gamma is present 
only in the brain and elucidates to a role for PKC gamma 
in driving the transformed phenotype in colon cancer. 
Our comprehensive gene expression analysis 
identified the presence of the gene coding PKC gamma 
in 57% of patient’s normal colon tissue and colon cancer 
tissue. This finding is intriguing as PKC gamma was 
Figure 1: Gene expression of PKC genes in colon cancer. Tissue samples measuring approximately 0.5cm in diameter were 
collected from 23 patients undergoing surgery in University Hospital Limerick. Normal tissue from the 23 patients was also collected 
approximately 10 cm away from the cancer tissue. RNA was extracted from the tissue, cDNA was synthesised and real time PCR was 
carried out. All data was normalized using the housekeeping genes PRGK1, GUSB, PPIA and HRPT1. (A) Fold change of PRKCG (PKC 
Gamma coding gene) in cancer tissue of each patient. Results were obtained by comparing mRNA level of PRKCG in individual’s normal 
tissue compared to levels in that individual’s cancer tissue (Statistical difference based on Pair Wise Fixed Reallocation Randomisation 
Test© as per REST© software). (B) Fold change of PRKCG in stage 2 cancer tissue. (C) Fold change of PRKCG in stage 3 cancer tissue (No 
statistical difference found between stages as determined by Mann Whitney U test). 
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traditionally thought to be only expressed in the brain 
[33, 34] and has also been used as a negative control for the 
colon [41]. Moreover, when comparing the expression of 
the PKC gamma coding gene in individual patients matched 
normal and colon cancer tissue we revealed an up-regulation 
of the gene in 54% of patient’s. This finding suggests that 
not only is PKC gamma present in the colon but it may also 
have a role to play in enhancing colon cancer.  
Having demonstrated that PKC gamma expression 
was expressed at high levels in the colon cancer patient 
tissue, we next considered the functional consequences 
of suppressing PKC gamma in colon cancer cells. 
Interestingly, when we suppressed PKC gamma in colon 
cancer cells there was a marked reduction in the size of 
spheroids developed in 3-dimensional culture. Further to 
this, we observed a dramatic decrease in the cells ability 
to form colonies in plating efficiency assays. Another 
key hallmark of cancer progression is an increase in the 
migratory capacity of cancer cells [42, 43]. Strikingly, 
we observed a significant reduction in the ability of cells 
to migrate when PKC gamma levels were reduced. This 
equates with previous research which demonstrates that 
PKC gamma phosphorylates nonmuscle myosin heavy 
chain II-B (NMHC-IIB) to increase cell motility of prostate 
cancer cells [38]. Moreover, a study examining PKC 
gamma in colon cancer cells revealed that PKC gamma 
interacts with Fascin and Rac at the edge of the cells to 
promote cell migration [37]. Taken together, this data 
suggests that PKC gamma has a tumour promoting role in 
colon cancer.
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We next examined the effect of suppressing 
PKC gamma on cell adhesion and proliferation and we 
observed a significant increase in both. Recent work has 
emerged clearly demonstrating that reduced proliferation 
is an integral part of the migratory phenotype [44, 45]. 
Interestingly, the latter study reveals that hyperproliferation 
is important for the initiation and maintenance of primary 
tumours but growth inhibition is crucial for the survival 
of carcinoma cells and hence leads to a more metastatic 
phenotype. Moreover, it has been demonstrated that PKC 
gamma is detected in higher levels in cell lines derived 
from advanced or metastatic colon cancer cells [46]. 
Considering this, we propose that PKC gamma may drive 
the migratory capacity inhibiting the proliferation of colon 
cancer cells. However, to fully elucidate this hypothesis 
rescue experiments in which the phenotype is reversed 
would need to be conducted. 
Collectively, the results in this study provide a strong 
argument that PKC gamma plays a key role in colon cancer 
and may have therapeutic benefits. However, animal 
model studies would need to be conducted to confirm that 
overexpression of the gene coding PKC gamma contributes 
to the metastatic potential of colon cancer. Following on 
from this it may be appropriate to consider drugs which 
target PKC gamma specifically.  
There is a growing body of evidence demonstrating 
a diversity of roles for the different PKC isozymes [20]. 
Consequently, the exact role of PKCs in cancer remains 
elusive, highlighting the importance of revisiting exactly 
how we target PKCs. The dogma that PKCs act as tumour 
promoters led to the development of several target therapies 
against cancer [4–6]. However, PKC inhibitors have 
proved unsuccessful as anti-cancer agents in clinical trials 
[4, 20, 32]. Further to this, recent evidence has emerged 
Figure 2: Effect of PKC Gamma knockdown on colon cancer cells. The effect of knockdown of PKC Gamma in colon cancer 
cells was examined using HCT116 cells transfected with an siRNA against PKC gamma. (A) The inverse of the Ct value obtained for the 
mRNA levels of PKC Gamma in HT29, LS174T and HCT116 cell lines. (B) Representative western blot demonstrating the expression 
of PKC Gamma in HT29 and HCT116 cell lines. (C) Representative western blot showing the expression percentage knockdown of 
PKC Gamma in HCT116 cells. (D) Images demonstrating the difference in the size of cells growing in a 3D matrix over 144 hours. Bar 
graph represents the percentage difference in the size of 3D cultures at 144 hours (Statistical difference based on Mann Whitney U test, 
**p < 0.01). (E) Representative images demonstrating the difference in the cells ability to form colonies when PKC gamma is reduced 
(Statistical difference based on Mann Whitney U test, ***p < 0.001). (F) Representative image of cells that were scored with a wound and 
allowed to migrate over 24 hours. Bar graph represents the percentage wound closer after 24 hours (Statistical difference based on Mann 
Whitney U test, ***p < 0.001). 
Oncotarget7www.impactjournals.com/oncotarget
indicating a tumour suppressor role for PKCs [7–9]. 
Much confusion surrounding the role of PKCs arises from 
contradictory immunohistochemical and biochemical 
studies which indicate altered expression of the PKC 
isozymes [21, 47, 48]. Recent commentary suggested 
that one of our biggest challenges in targeting PKCs is 
the limited data available on patient samples, and, the 
difficulties associated with translating animal models in 
the clinic [32]. Here, using human tissue we have clearly 
demonstrated the abundant expression of the gene coding 
PKC gamma in the colon tissue. 
This human expression data combined with our cell 
based assays strongly suggests that PKC gamma plays a 
role in colon cancer. This study together with the emerging 
contradictory arguments showing both tumour suppressor 
and tumour promoter roles for PKCs [20] clearly 
highlights the need to revisit individual PKC isozymes in 
a tissue specific manner. 
MATERIALS AND METHODS 
Clinical Samples
A cohort of colorectal tissue samples were collected, 
with ethical approval from the University Hospital 
Limerick’s Ethics Committee, from 23 patients (median 
age 69 y; range, 45–85; male 15, female 8) undergoing 
surgery in University Hospital Limerick. One patient had 
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stage 1, 14 patients had stage 2 and 8 patients had stage 
3 colon cancer. Normal tissue from the 23 patients was 
also collected approximately 10 cm away from the tumour 
tissue. Specimens were immediately placed in Allprotect 
tissue reagent (Qiagen) and stored at –80°C. 
RNA extraction and cDNA synthesis 
Frozen tissue was immersed in liquid nitrogen and 
ground into powder. Lysis buffer was added to tissue and 
the sample transferred to tubes using a 21-gauge needle. 
Total RNA was extracted as per Qiagen RNeasy Mini 
Kit instructions. RNA was quantified using a Nanodrop 
Spectrophotometer (Thermo Scientific) and stored at 
–80 degrees. RNA purity was evaluated by the ratio of 
absorbance at 260/280 nm and RNA quality was evaluated 
through visualization of the 28S:18S ribosomal RNA ratio 
on a 1% agarose gel. Total RNA (1 μg) was synthesised 
into cDNA using Vilo cDNA synthesis kit (Invitrogen) and 
stored at –20 degrees. 
Real-time PCR
Real-time PCR was conducted using the ABI 
7900 HT instrument (Applied Biosystems) following 
supplier instructions. Taqman® Gene Expression Assay 
Figure 3: Effect of PKC Gamma knockdown on proliferation of colon cancer cells. The effect of knockdown of PKC Gamma 
on proliferation in colon cancer cells was examined using the real-time cell analysis xCELLigence system and traditional cell growth assays. 
(A) Representative graph of HCT116 cells proliferating over a period of 24 hours analysed in real time on the xCELLigence system. Bar 
graph represents the rate of proliferation as determined by averaging the cell index over 24 hours (Statistical difference based on Mann 
Whitney U test, ***p < 0.001). (B) Graph indicating cell growth at 24 hr and 48 hr in HCT116 cells as determined by the traditional cell 
growth assay. Bar graph represents the percentage difference in cell number at 24 hr and 48 hr (Statistical difference based on Mann Whitney 
U test, ***p < 0.001). (C) Graph indicating cell growth at 24 hr and 48 hr in HT29 cells as determined by the traditional cell growth assay. Bar 
graph represents the percentage difference in cell number at 24 hr and 48 hr (Statistical difference based on Mann Whitney U test, **p < 0.01).
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Kits (Applied Biosystems) were used to analyse the gene 
expression of the PKC gamma coding gene. A panel of nine 
housekeeping genes were evaluated using excel Normfinder 
and the four most stable genes were used for normalisation 
of each experiment. 
Cell culture and transfection 
HCT116, HT29 and LS174T colorectal carcinoma 
cells were purchased from ATCC (ATCC® CCL-247™ 
with certificates of analysis) and were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM) (Sigma), 
supplemented with 10% (v/v) fetal calf serum, 10 mM 
L-Glu, and 5 mg/ml penicillin/streptomycin. Cells were 
transiently transfected with siRNA oligonucleotide against 
PKC gamma and a control oligonucleotide, using the 
NEON transfection system® (Thermo Fisher Scientific) 
as per manufactures instructions. After 24 h in culture, 
cells were treated as described in the figures. PKC gamma 
levels were analysed using a total PKC gamma antibody 
(Santa Cruz, sc-211).
3-Dimensional cell cultures 
Individual wells of a 6 well plate were coated with 
MatrigelTM (BD Biosciences) and placed in an incubator at 
37°C for 30 min. Transfected cells were trypsinized and 
counted. 50,000 cells/ml were resuspended in DMEM 
supplemented with 2% MatrigelTM. Cells were placed in 
MatrigelTM coated wells for 30 min at 37°C, after which 
DMEM supplemented with 2% MatrigelTM was added to 
the cultures. Cells were maintained in culture for 6 days in 
an incubator at 37°C, 5% CO2 with fresh medium added 
every 2 days and cultures imaged every 24 hours (Olympus 
cellSens Dimension 1.12). 
Colony formation assay 
Transfected cells were harvested with trypsin/
EDTA, washed with DMEM and counted using a 
haemocytometer. 500 cells were plated per well of a 
6 well plate and incubated at 37°C in 5% CO2 for 10 days. 
Following this time, the cells were fixed in 96% ethanol 
Figure 4: Effect of PKC Gamma knockdown on adherence of colon cancer cells. The effect of knockdown of PKC Gamma on 
adherence in colon cancer cells was examined using the real-time cell analysis xCELLigence system and traditional cell adherence assays. 
(A) Representative graph of HCT116 cells adhering over a period of 5 hours analysed in real time on the xCELLigence system. Bar graph 
represents the rate of adhesion determined by averaging the cell index over 5 hours (Statistical difference based on Mann Whitney U test, 
***p < 0.001). (B) Bar graph showing the difference in cell adherence for crystal violet stained HCT116 cells, absorbance was determined 
at 595 nm after 3 hours (Statistical difference based on Mann Whitney U test, **p < 0.01).
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for 10 min and subsequently stained with 0.05% crystal 
violet for 20 min. The wells were washed carefully and 
allowed to dry. Colonies were counted and recorded and a 
colony was deemed to be of 50 cells or more in size. 
Scratch wound assay 
Adhesive wound assay inserts (Ibidi) were used to 
generate wounds in confluent layers in a 6 well plate. To 
do this, transfected cells were trypsinized and seeded into 
the plate to form a monolayer. After overnight growth 
and attachment, the insert was carefully removed and the 
cells were starved of serum by adding serum free media 
for 4 hours, after which DMEM was added to the cells 
and they were imaged immediately (T0) using (Olympus 
cellSens Dimension 1.12). Cells were maintained in an 
incubator at 37°C, 5% CO2 for 24 hours, after which time 
images of the wound closure were taken as described 
above. The percentage wound closure was analysed using 
Wimasis image analysis. 
Proliferation and adherence assay 
The rate of proliferation and adherence was 
monitored in real time using the xCELLigence E-plate 
system. Either 30,000 HCT116 cells transfected with 
siRNA oligonucleotide against PKC gamma or 30,000 
HCT116 cells transfected with a control oligonucleotide 
were placed in each well. The impedance value of each 
well was automatically monitored by the xCELLigence 
system (xCELLigence RTCA DP, ACEA) for duration of 
24 hours and expressed as a cell index value (CI). For cell 
growth assays cells were transfected as above and seeded 
at 50,000 cells, following 24 and 48 hours of growth, cells 
were trypsinised and counted in triplicate. 
Statistical analysis 
Statistical analysis was performed using SPSS 20 
Statistical Package unless stated otherwise. Significance 
between two groups was determined by the Mann Whitney 
U Test. For matched patient samples differences in gene 
expression levels was determined for each individual 
patient using Pair Wise Fixed Reallocation Randomisation 
Test© as per REST© software. For all statistical analysis 
differences were considered to be statistically significant 
at p < 0.05. 
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